Hengrui Pharmaceuticals: Clinical trials will be conducted on fluorine palli capsules and apatini tablets of methulphate

On February 19, Hengrui Pharmaceuticals announced that it had recently received a "Notice of Approval for Clinical Trials of Drugs" issued by the State Drug Administration for fluoroazole capsules and apatini tablets of meth sulfonate, and that clinical trials would be conducted in the near future.
Fluorofolpali capsules are used in the treatment of patients with platinum-sensitive relapsed ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who have underwent second-line and above chemotherapy with embryoline BRCA mutations (gBRCAm);
's fluoroazole Pali capsule was approved by the National Drug Administration on December 11, 2020 for the treatment of patients with platinum-sensitive reocgenerative ovarian, fallopian or primary peritoneal cancer who have underwent second-line and above chemotherapy with embryoline BRCA mutations (gBRCAm).
In January 2021, the maintenance treatment of platinum-sensitive relapsed epitheliotic ovarian, fallopian or primary peritina cancer after platinum-containing chemotherapy has reached full or partial remission has been included in the priority review by the Drug Review Center of the National Drug Administration.
In addition to treatment for platinum-sensitive relapsed ovarian, fallopian tube or primary peritoneal cancer, multiple adaptation developments for fluoroazole capsule monodones or co-methafylatin tablets are already in III During the clinical study phase, a variety of other combination therapies, including combination with abitor, combination with the anti-PD-L1 antibody SHR-1316, and combination therapy of multiple solid tumors with tymoamine, are already in clinical development.
fluorine palate is a poly-ADP-ribose ribase (poly-ribose) polymerase (PARP) inhibitor that specifically kills tumor cells with BRCA mutations.
inquiries, Olaparib (commodity name Lynparza), Rucaparib (product name Rubraca), Niraparib (commodity name Zejula) and Talazoparib (commodity name Talzenna) were approved for sale in the United States, Olaparib (commodity name Lynparza) was approved for sale in China in August 201.
's domestic re-ding pharmaceutical toluene sulfonate nirapali capsule (commodity name Cyrel) was approved for listing in China in December 2019 for maintenance therapy in adult patients with platinum-sensitive relapsed epithelyl ovarian cancer, fallopian tube cancer or primary peritoneal cancer after platinum-containing chemotherapy has reached full or partial remission.
2019, Olaparib (product name Lynparza), Rucaparib (product name Rubraca), Niraparib (product name Zejula) and Talazoparib (product name Talzenna) have global sales of approximately $1,357 million and U.S. sales of approximately $674 million.
, the cumulative investment in research and development costs for fluorine-related projects has been approximately 314.05 million yuan.
Apatini has been approved by the State Drug Administration in November 2014 for patients with advanced gastric adenocarcinoma or gastric-esophageal combined adenocarcinoma who have progressed or relapsed after at least 2 systematic chemotherapy in the past, and by the State Drug Administration in December 2020 for patients with advanced hepatocellular carcinoma who have failed or are not acceptable after receiving at least one systematic treatment in the past.
inquiries, at present at home and abroad have Sorafeini, Shonitini, Pezparni and other similar products approved for listing.
Sorafoni was developed by Bayer and first approved for listing in the United States in 2005;
, Soraphoni, Shonitini and Pezopani are all listed in China.
, Solaphoni, Shonitini and Peropani combined global sales of approximately $2,159 million in 2019.
, the cumulative investment in research and development costs for Apatini-related projects has been approximately 390.25 million yuan.